Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Military briefing: Ukraine’s daring ‘shaping operations’ stretch Russian defences
    • Moscow attacked by drones as Kyiv bombarded for third straight day
    • Russia pounds Ukraine with missile and drone barrage
    • Turkey’s lira weakens as economists warn of Erdoğan’s ‘unsustainable’ policies
    • China turns down US invitation for defence chiefs’ meeting in Singapore
  • UK
    Sections
    • UK Home
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
    Most Read
    • Labour plans to tackle housing crisis by forcing landowners to sell at lower prices
    • UK shop price inflation rises to record high, industry data shows
    • ‘We are all thinking about how to contribute’: Hongkongers boost Britain’s suburbs
    • Cabinet Office in stand-off with Covid inquiry over Boris Johnson messages
    • Tony Blair Institute proposes ‘radical’ UK pension superfunds
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • India files criminal complaint against Rolls-Royce and BAE
    • German start-up wins initial funding for revolutionary fusion energy machine
    • Philip Morris on path to becoming an ESG stock, says chief executive
    • Interest rate rises set back European bank M&A by two years
    • Temasek cuts pay of employees behind failed $275mn bet on FTX
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • Live news: Vladimir Putin promises response to Moscow drone strikes
    • Turkey’s lira weakens as economists warn of Erdoğan’s ‘unsustainable’ policies
    • Philip Morris on path to becoming an ESG stock, says chief executive
    • Temasek cuts pay of employees behind failed $275mn bet on FTX
    • Wall Street banks re-enter junk debt market
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Don’t bet against the ‘suitcase principle’ of white-collar work
    • How to buy a global $20bn company for nothing
    • The UK needs a new deal for its highly taxed graduates
    • De-risking trade with China is a risky business
    • America’s horse deaths bode ill for the sport of kings
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • ‘Everyone has the right to completely log off’: what bosses think about the right to disconnect
    • Wellcome Leap’s Regina Dugan: ‘Odds are irrelevant, if what you’re trying to do is important’
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • The UK’s best bakeries: the readers’ picks
    • Succession finale review — one last twist of the knife
    • Who makes the best butter?
    • The treasures of Mallorca’s Tramuntana mountains
    • The best summer road cycling gear
  • HTSI
MenuSearch
  • Home
  • World
  • UK
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Biogen Inc

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Monday, 8 May, 2023
    Dementia
    Two Alzheimer’s drugs offer hope to patients after decades of waiting

    In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide

  • Thursday, 4 May, 2023
    AstraZeneca PLC
    AstraZeneca chair says it is paying CEO enough to ward off US rivals

    Drugmaker’s chief executive Pascal Soriot had talks last year about a role with US group Biogen

  • Thursday, 29 December, 2022
    Congress faults US regulator’s approval of Biogen Alzheimer’s drug

    Committees cite inappropriate collaboration between FDA and drugmaker

  • Friday, 2 December, 2022
    The editorial board
    A glimmer of hope in treating Alzheimer’s disease

    Dementia drug development, diagnostics and delivery still require much more investment

  • Tuesday, 29 November, 2022
    Eisai Co Ltd
    Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug

    Shares fall 11% following two patient deaths in trials of lecanemab

  • Monday, 28 November, 2022
    LexDrugs research
    Dementia/Biogen: causal controversy means investors must take a stance Premium content

    The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down

  • Wednesday, 28 September, 2022
    Pharmaceuticals sector
    Biogen and Eisai shares surge after Alzheimer’s drug trial success

    Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease

  • Friday, 23 September, 2022
    Health sector
    Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory

    Study of Eisai treatment will be one of last chances to prove amyloid hypothesis, say experts

  • Wednesday, 21 September, 2022
    Pharmaceuticals sector
    Biogen drug slows progress of motor neurone disease in landmark trial

    Tofersen targets a defective gene that causes about 2% of cases of MND, also known as amyotrophic lateral sclerosis

  • Wednesday, 4 May, 2022
    FT News Briefing podcast8 min listen
    Draghi urges EU to abandon unanimity requirement

    Biogen chief to step down after the company’s Alzheimer’s drug flops

  • Tuesday, 3 May, 2022
    Biogen chief to step down after Alzheimer’s drug flops

    US biotech to dismantle sales infrastructure for treatment as it begins search for successor

  • Sunday, 17 April, 2022
    Anjana Ahuja
    Hasty approval for Alzheimer’s drug offers a cautionary tale

    FDA’s green light for aducanumab may delay development of more effective treatments for dementia, critics say

  • Monday, 20 December, 2021
    Biogen halves price of Alzheimer’s drug after sales fall short

    Insurers’ reluctance to pay for Aduhelm treatment forces biotech to lower costs as EMA highlights safety concerns

  • Wednesday, 17 November, 2021
    European regulators cast doubt on Biogen Alzheimer’s drug

    Vote by European Medicines Agency panel deals setback to controversial $56,000-a-year treatment

  • Wednesday, 20 October, 2021
    Biogen sells just $300,000 worth of contentious Alzheimer’s drug

    Third-quarter revenues from $56,000-per-year treatment were well below analysts’ expectation of $10m

  • Thursday, 22 July, 2021
    Biogen defends contentious $56,000 Alzheimer’s drug

    Pharma group blames ‘misinformation’ for overshadowing approval of therapy

  • Friday, 9 July, 2021
    US Food & Drug Administration
    FDA calls for probe of staff involved in divisive Alzheimer’s approval

    US drugs watchdog was under pressure after scientific outcry over controversial Biogen treatment

  • Monday, 5 July, 2021
    News in-depthPharmaceuticals sector
    Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

    Hypothesis that brain plaques cause disease viewed with scepticism by some scientists

  • Wednesday, 16 June, 2021
    Pharmaceuticals sector
    Biogen’s Japanese partner calls for global action on Alzheimer’s

    Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’

  • Friday, 11 June, 2021
    The Big Read
    The Alzheimer’s economy: is the new $56,000-a-year drug worth it?

    US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high

  • Tuesday, 8 June, 2021
    The FT ViewThe editorial board
    How to make the most of the Alzheimer’s drug approval

    FDA decision on aducanumab must bring benefits beyond Biogen’s bottom line

  • Tuesday, 8 June, 2021
    Lex
    Biogen/Alzheimer’s: the high cost of hope Premium content

    Lofty prices reward risky, expensive research. But aducanumab’s pricing will raise eyebrows

  • Tuesday, 8 June, 2021
    Drug prices
    Biogen’s $56,000-a-year Alzheimer’s drug reignites US debate over costs

    Campaigners hit out at high price for controversial treatment that has divided scientists

  • Monday, 7 June, 2021
    Pharmaceuticals sector
    Alzheimer’s drug from Biogen wins US approval

    FDA signs off on first new treatment for disease in almost 20 years despite controversy over efficacy

  • Monday, 7 June, 2021
    Q&ADrugs research
    Alzheimer’s sufferers await ruling on potential blockbuster drug

    Biogen’s aducanumab would be first new treatment in years for disease if approved by FDA

Previous page You are on page 1 Next page

Be part of FT Community

Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

FT Live
US Pharma and Biotech Summit
Exploring trends and innovations in life sciences across the United States
Tuesday, 14th May 2024New York, US & Online
Learn more about FT Community

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsFT Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

UK Edition

Subscribe for full access
  • Switch to International Edition

Top sections

  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • UK
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In